Unveiling quality of clinical trial in China: from concern to confirmation

References

[1] Li N, Huang HY, Wu DW, Yang ZM, Wang J, Wang JS, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review. Lancet Oncol. 2019;20(11):e619-e626.

[2] Huang H, Wu D, Miao H, Tang Y, Liu C, Fang H, et al. Accelerating the integration of China into the global development of innovative anticancer drugs. Lancet Oncol. 2022;23(11):e515-e520.

[3] Woodhead M. 80% of China's clinical trial data are fraudulent, investigation finds. BMJ. 2016;355:i5396.

[4] Cyranoski D. China cracks down on fake data in drug trials. Nature. 2017;545(7654):275.

[5] Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y, et al. Pharmacovigilance in China: Evolution and future challenges. Br J Clin Pharmacol. 2023;89(2):510-522.

[6] National Medical Products Administration. Website of ICH work office [2023 08-20]. Available from:

[7] U.S Food and Drug Administration. Dashboards - Compliance Dashboards [2023 08-20]. Available from:

[8] Ma Y, Wang Q, Duan Y, Shi Q, Zhang X, Yang K, et al. Promoting the quality and transparency of health research in China. J Clin Epidemiol. 2022;152:209-217.

[9] Liu Y, Zhang N, Xie C, Jiang Y, Qin Y, Zhou L, et al. Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharm Sin B. 2022;12(12):4365-4377.

RIGHTS & PERMISSIONS

2024 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd on behalf of Sun Yat-sen University Cancer Center.